Legal & General Group Plc Grows Stock Holdings in Icon Plc $ICLR

Posted by Geri Gentry on Jun 1st, 2026

Legal & General Group Plc grew its position in Icon Plc (NASDAQ:ICLR – Free Report) by 7.7% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 147,715 shares of the medical research company’s stock after buying an additional 10,609 shares during the quarter. Legal & General Group Plc’s holdings in Icon were worth $26,917,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also recently bought and sold shares of ICLR. WINTON GROUP Ltd acquired a new position in Icon in the 2nd quarter valued at about $254,000. Daiwa Securities Group Inc. grew its position in Icon by 19.3% in the 2nd quarter. Daiwa Securities Group Inc. now owns 28,145 shares of the medical research company’s stock valued at $4,094,000 after acquiring an additional 4,546 shares in the last quarter. Frontier Capital Management Co. LLC grew its position in Icon by 97.6% in the 2nd quarter. Frontier Capital Management Co. LLC now owns 71,360 shares of the medical research company’s stock valued at $10,379,000 after acquiring an additional 35,253 shares in the last quarter. Peapack Gladstone Financial Corp acquired a new position in Icon in the 2nd quarter valued at about $212,000. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in Icon by 58.7% in the 2nd quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 781 shares of the medical research company’s stock valued at $113,000 after acquiring an additional 289 shares in the last quarter. Institutional investors and hedge funds own 95.61% of the company’s stock.

Trending Headlines about Icon

Here are the key news stories impacting Icon this week:

Positive Sentiment: BMO Capital Markets raised its target on Icon Plc to $160 from $130 and kept an outperform rating, suggesting meaningful upside potential. Benzinga
Positive Sentiment: Barclays lifted its price target to $150 from $120, with an equal weight rating, signaling improved expectations for the stock. Tickerreport.com
Positive Sentiment: Citigroup increased its target to $140 from $120, implying modest upside from current levels, though it kept a neutral stance. Tickerreport.com
Neutral Sentiment: JPMorgan raised its target to $130 from $120 but kept a neutral rating, reflecting a more cautious view than some peers. Benzinga
Neutral Sentiment: Icon reported fourth-quarter earnings that missed estimates, but revenue came in above expectations and the company highlighted strong bookings despite ongoing revenue challenges. Yahoo Finance
Negative Sentiment: Icon disclosed a material weakness in internal controls, which raises concerns about financial reporting quality and potential regulatory risk. TipRanks
Negative Sentiment: The company also cut FY 2026 EPS guidance to $10.00-$11.00, below Wall Street expectations, which likely pressured the stock after earnings. Financial News

Wall Street Analyst Weigh In

Several equities analysts have weighed in on the company. BMO Capital Markets lifted their target price on Icon from $130.00 to $160.00 and gave the company an “outperform” rating in a research report on Friday. Piper Sandler downgraded Icon to a “neutral” rating in a research report on Thursday. JPMorgan Chase & Co. lifted their target price on Icon from $120.00 to $130.00 and gave the company a “neutral” rating in a research report on Friday. Royal Bank Of Canada lifted their target price on Icon from $123.00 to $126.00 and gave the company a “sector perform” rating in a research report on Friday. Finally, Truist Financial boosted their price objective on Icon from $139.00 to $159.00 and gave the stock a “hold” rating in a research report on Friday. Seven analysts have rated the stock with a Buy rating, eight have given a Hold rating and three have assigned a Sell rating to the company’s stock. According to data from MarketBeat, Icon currently has an average rating of “Hold” and a consensus target price of $153.00.

Check Out Our Latest Report on ICLR

Icon Stock Performance

Shares of Icon stock opened at $136.07 on Monday. Icon Plc has a one year low of $66.57 and a one year high of $211.00. The company has a market cap of $10.99 billion, a PE ratio of 22.09, a P/E/G ratio of 3.55 and a beta of 1.26. The company has a debt-to-equity ratio of 0.31, a quick ratio of 1.10 and a current ratio of 1.10. The business has a 50-day simple moving average of $113.06 and a 200-day simple moving average of $141.35.

Icon (NASDAQ:ICLR – Get Free Report) last posted its earnings results on Wednesday, June 3rd. The medical research company reported $2.52 earnings per share for the quarter, missing the consensus estimate of $2.95 by ($0.43). The business had revenue of $2.11 billion for the quarter, compared to analysts’ expectations of $1.99 billion. Icon had a return on equity of 9.50% and a net margin of 5.98%.Icon’s revenue for the quarter was up 2.5% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $3.43 EPS. On average, equities research analysts forecast that Icon Plc will post 11.53 EPS for the current fiscal year.

Icon Profile

(Free Report)

Icon plc (NASDAQ: ICLR) is a global provider of outsourced drug development and clinical research services to the pharmaceutical, biotechnology and medical device industries. The company partners with clients at all stages of the product life cycle, offering expertise in protocol design, trial execution and regulatory compliance across a broad range of therapeutic areas.

Icon’s service portfolio encompasses clinical trial management, data management and biostatistics, medical imaging, pharmacovigilance and safety monitoring, laboratory sciences and specialized analytical solutions.